Compare Supplements

Approved (postmenopausal women) / off-label (male) — clinician-directed. For osteoporosis treatment/prevention and breast-cancer risk reduction the standard, validated dose is 60 mg once daily (the MORE, CORE, RUTH and STAR trials all used 60 mg/day; MORE also tested 120 mg/day with no clear added fracture benefit and more side effects). For off-label male gynecomastia the small published pediatric series used roughly 60 mg/day; there is no FDA-approved male dose and the male evidence is thin and retrospective.

Any time

Raloxifene hydrochloride 60 mg tablets (approved for postmenopausal osteoporosis and breast-cancer risk reduction)

300mg standardized extract

With meals · with food

Standardized extract (300–600 mg, 2.5% rosmarinic acid)

• Active or past history of venous thromboembolism (deep-vein thrombosis, pulmonary embolism, retinal-vein thrombosis) — raloxifene raises clot risk
• Pregnancy and breastfeeding (can harm the fetus; contraindicated)
• Women of childbearing potential / premenopausal women (not indicated)

• Warfarin / anticoagulants
• Cholestyramine
• Systemic estrogens / other SERMs / aromatase inhibitors

• Epilepsy or seizure disorders (thujone content may lower seizure threshold)
• Pregnancy (may stimulate uterine contractions; avoid therapeutic doses)
• Hormone-sensitive cancers (estrogenic activity; consult oncologist)

• Anticoagulants (warfarin, heparin)
• Antidiabetic drugs (metformin, insulin, sulfonylureas)
• Anticonvulsants (phenytoin, valproate, carbamazepine)